During the past decade, The Urology Group conducted 16 clinical trials. In the 10-year time frame, 16 clinical trials started and 19 clinical trials were completed, i.e. on average, 118.8% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 9 clinical trials were completed. i.e. 180% of trials that started reached the finish line.

Out of the total clinical trials conducted in "The Urology Group" #1 sponsor was "Pfizer" with 6 trials, followed by "GTx" with 5 trials sponsored, "Dendreon" with 3 trials sponsored, "Endo Pharmaceuticals" with 3 trials sponsored and "Janssen Research & Development, LLC" with 3 trials sponsored. Other sponsors include 18 different institutions and companies that sponsored additional 23 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "The Urology Group" #1 collaborator was "Astellas Pharma Inc" with 3 trials as a collaborator, "Foundation Medicine" with 2 trials as a collaborator, "Medivation LLC, a wholly owned subsidiary of Pfizer Inc." with 2 trials as a collaborator, "GlaxoSmithKline" with 1 trials as a collaborator and "Regulatory and Clinical Research Institute (RCRI)" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "The Urology Group" are "Prostate Cancer" (8 trials), "Prostatic Neoplasms" (4 trials), "Stress Urinary Incontinence" (4 trials), "Peyronie's Disease" (3 trials) and "Adult Male Hypogonadism" (2 trials). Many other conditions were trialed in "The Urology Group" in a lesser frequency.

Most popular intervention types in "The Urology Group" are "Drug" (30 trials), "Biological" (10 trials), "Other" (3 trials), "Device" (2 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (10 trials), "AA4500" (3 trials), "Enzalutamide" (3 trials), "GTx-024" (2 trials) and "Rucaparib" (2 trials). Other intervention names were less common.

The vast majority of trials in "The Urology Group" are 27 trials for "Male" genders, 12 trials for "All" genders and 4 trials for "Female" genders.

Currently, there are NaN active trials in "The Urology Group". undefined are not yet recruiting, 3 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 29 completed trials in The Urology Group, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in The Urology Group, 0 "Phase 1" clinical trials were conducted, 17 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 4 trials that are defined as “Not Applicable".